Neuroprotection against traumatic brain injury by xenon, but not argon, is mediated by inhibition at the n-methyl-d-aspartate receptor glycine site

Anesthesiology

Volumn 119, Issue 5, 2013, Pages 1137-1148

  Harris, Katie ^a   Armstrong, Scott P ^a   Campos Pires, Rita ^a   Kiru, Louise ^a   Franks, Nicholas P ^a   Dickinson, Robert ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGON; GLYCINE; GLYCINE RECEPTOR; HELIUM; KRYPTON; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEON; NEUROPROTECTIVE AGENT; POTASSIUM CHANNEL; PROPIDIUM IODIDE; STRYCHNINE; TREK 1 CHANNEL; UNCLASSIFIED DRUG; XENON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CELL DAMAGE; CELL STRAIN HEK293; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; ENZYME INHIBITION; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NEUROPROTECTION; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; TRAUMATIC BRAIN INJURY;

AIR PRESSURE; ANESTHETICS, INHALATION; ANIMALS; ARGON; ATMOSPHERE EXPOSURE CHAMBERS; BRAIN INJURIES; CA1 REGION, HIPPOCAMPAL; CELL COUNT; CELL LINE; ELECTROPHYSIOLOGICAL PROCESSES; GLYCINE; HIPPOCAMPUS; HUMANS; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; ORGAN CULTURE TECHNIQUES; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; XENON;

EID: 84888289410     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3182a2a265     Document Type: Article

References (67)

1. Bruns J Jr, Hauser WA: The epidemiology of traumatic brain injury: A review. Epilepsia 2003; 44(suppl 10):2-10
2. Langlois JA, Rutland-Brown W, Wald MM: The epidemiology and impact of traumatic brain injury: A brief overview. J Head Trauma Rehabil 2006; 21:375-8
3. Tolias CM, Bullock MR: Critical appraisal of neuroprotection trials in head injury: What have we learned? NeuroRx 2004; 1:71-9
4. Wang KK, Larner SF, Robinson G, Hayes RL: Neuroprotection targets after traumatic brain injury. Curr Opin Neurol 2006; 19:514-9
5. Warner DS, Borel CO: Treatment of traumatic brain injury: One size does not fit all. Anesth Analg 2004; 99:1208-10
6. Greve MW, Zink BJ: Pathophysiology of traumatic brain injury. Mt Sinai J Med 2009; 76:97-104
7. Ling GS, Marshall SA: Management of traumatic brain injury in the intensive care unit. Neurol Clin 2008; 26:409-26, viii
8. Loane DJ, Faden AI: Neuroprotection for traumatic brain injury: Translational challenges and emerging therapeutic strategies. Trends Pharmacol Sci 2010; 31:596-604
9. Raghupathi R: Cell death mechanisms following traumatic brain injury. Brain Pathol 2004; 14:215-22
10. Teasdale GM, Graham DI: Craniocerebral trauma: Protection and retrieval of the neuronal population after injury. Neurosurgery 1998; 43:723-37; discussion 737-8
11. Bullock R, Zauner A, Myseros JS, Marmarou A, Woodward JJ Young HF: Evidence for prolonged release of excitatory amino acids in severe human head trauma: Relationship to clinical events. Ann N Y Acad Sci 1995; 765:290-7
12. Kochanek PM, Clark RS, Ruppel RA, Adelson PD, Bell MJ, Whalen MJ, Robertson CL, Satchell MA, Seidberg NA, Marion DW, Jenkins LW: Biochemical, cellular, and molecular mechanisms in the evolution of secondary damage after severe traumatic brain injury in infants and children: Lessons learned from the bedside. Pediatr Crit Care Med 2000; 1:4-19
13. Nilsson P, Hillered L, Pontén U, Ungerstedt U: Changes in cortical extracellular levels of energy-related metabolites and amino acids following concussive brain injury in rats. J Cereb Blood Flow Metab 1990; 10:631-7
14. Wilhelm S, Ma D, Maze M, Franks NP: Effects of xenon on in vitro and in vivo models of neuronal injury. Anesthesiology 2002; 96:1485-91
15. Ma D, Wilhelm S, Maze M, Franks NP: Neuroprotective and neurotoxic properties of the 'inert' gas, xenon. Br J Anaesth 2002; 89:739-46
16. Banks P, Franks NP, Dickinson R: Xenon neuroprotection against hypoxia-ischaemia is mediated by the N-methyl-Daspartate receptor glycine site. Br J Anaesth 2010; 104:526
17. Dingley J, Tooley J, Porter H, Thoresen M: Xenon provides short-term neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke 2006; 37:501-6
18. Fries M, Nolte KW, Coburn M, Rex S, Timper A, Kottmann K, Siepmann K, Häusler M, Weis J, Rossaint R: Xenon reduces neurohistopathological damage and improves the early neurological deficit after cardiac arrest in pigs. Crit Care Med 2008; 36:2420-6
19. Coburn M, Maze M, Franks NP: The neuroprotective effects of xenon and helium in an in vitro model of traumatic brain injury. Crit Care Med 2008; 36:588-95
20. Ma D, Hossain M, Chow A, Arshad M, Battson RM, Sanders RD, Mehmet H, Edwards AD, Franks NP, Maze M: Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Ann Neurol 2005; 58:182-93
21. Homi HM, Yokoo N, Ma D, Warner DS, Franks NP, Maze M, Grocott HP: The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. Anesthesiology 2003; 99:876-81
22. Sheng SP, Lei B, James ML, Lascola CD, Venkatraman TN, Jung JY, Maze M, Franks NP, Pearlstein RD, Sheng H, Warner DS: Xenon neuroprotection in experimental stroke: Interactions with hypothermia and intracerebral hemorrhage. Anesthesiology 2012; 117:1262-75
23. Bickler PE, Warren DE, Clark JP, Gabatto P, Gregersen M, Brosnan H: Anesthetic protection of neurons injured by hypothermia and rewarming: Roles of intracellular Ca2+ and excitotoxicity. Anesthesiology 2012; 117:280-92
24. Preckel B, Weber NC, Sanders RD, Maze M, Schlack W: Molecular mechanisms transducing the anesthetic, analgesic, and organ-protective actions of xenon. Anesthesiology 2006; 105:187-97
25. Oei GT, Weber NC, Hollmann MW, Preckel B: Cellular effects of helium in different organs. Anesthesiology 2010; 112:1503-10
26. Dickinson R, Franks NP: Bench-to-bedside review: Molecular pharmacology and clinical use of inert gases in anesthesia and neuroprotection. Crit Care 2010; 14:229
27. Ryang YM, Fahlenkamp AV, Rossaint R, Wesp D, Loetscher PD, Beyer C, Coburn M: Neuroprotective effects of argon in an in vivo model of transient middle cerebral artery occlusion in rats. Crit Care Med 2011; 39:1448-53
28. Loetscher PD, Rossaint J, Rossaint R, Weis J, Fries M, Fahlenkamp A, Ryang YM, Grottke O, Coburn M: Argon: Neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury. Crit Care 2009; 13:R206
29. Yarin YM, Amarjargal N, Fuchs J, Haupt H, Mazurek B, Morozova SV, Gross J: Argon protects hypoxia-, cisplatin-and gentamycin-exposed hair cells in the newborn rat's organ of Corti. Hear Res 2005; 201:1-9
30. Zhuang L, Yang T, Zhao H, Fidalgo AR, Vizcaychipi MP, Sanders RD, Yu B, Takata M, Johnson MR, Ma D: The protective profile of argon, helium, and xenon in a model of neonatal asphyxia in rats. Crit Care Med 2012; 40: 1724-30
31. David HN, Haelewyn B, Degoulet M, Colomb DG Jr, Risso JJ, Abraini JH: Ex vivo and in vivo neuroprotection induced by argon when given after an excitotoxic or ischemic insult. PLoS One 2012; 7:e30934
32. David HN, Haelewyn B, Chazalviel L, Lecocq M, Degoulet M, Risso JJ, Abraini JH: Post-ischemic helium provides neuroprotection in rats subjected to middle cerebral artery occlusion-induced ischemia by producing hypothermia. J Cereb Blood Flow Metab 2009; 29:1159-65
33. Pan Y, Zhang H, VanDeripe DR, Cruz-Flores S, Panneton WM: Heliox and oxygen reduce infarct volume in a rat model of focal ischemia. Exp Neurol 2007; 205:587-90
34. Banks P, Franks NP, Dickinson R: Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor mediates xenon neuroprotection against hypoxia-ischemia. Anesthesiology 2010; 112:614-22
35. Jawad N, Rizvi M, Gu J, Adeyi O, Tao G, Maze M, Ma D: Neuroprotection (and lack of neuroprotection) afforded by a series of noble gases in an in vitro model of neuronal injury. Neurosci Lett 2009; 460:232-6
36. Franks NP, Dickinson R, de Sousa SL, Hall AC, Lieb WR: How does xenon produce anaesthesia? Nature 1998; 396:324
37. Dickinson R, Peterson BK, Banks P, Simillis C, Martin JC, Valenzuela CA, Maze M, Franks NP: Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor by the anesthetics xenon and isoflurane: Evidence from molecular modeling and electrophysiology. Anesthesiology 2007; 107:756-67
38. Armstrong SP, Banks PJ, McKitrick TJ, Geldart CH, Edge CJ, Babla R, Simillis C, Franks NP, Dickinson R: Identification of two mutations (F758W and F758Y) in the N-methyl-D-aspartate receptor glycine-binding site that selectively prevent competitive inhibition by xenon without affecting glycine binding. Anesthesiology 2012; 117:38-47
39. Stoppini L, Buchs PA, Muller D: A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 1991; 37:173-82
40. Adamchik Y, Frantseva MV, Weisspapir M, Carlen PL, Perez Velazquez JL: Methods to induce primary and secondary traumatic damage in organotypic hippocampal slice cultures. Brain Res Brain Res Protoc 2000; 5:153-8
41. Macklis JD, Madison RD: Progressive incorporation of propidium iodide in cultured mouse neurons correlates with declining electrophysiological status: A fluorescence scale of membrane integrity. J Neurosci Methods 1990; 31:43-6
42. Gruss M, Bushell TJ, Bright DP, Lieb WR, Mathie A, Franks NP: Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol 2004; 65:443-52
43. de Sousa SL, Dickinson R, Lieb WR, Franks NP: Contrasting synaptic actions of the inhalational general anesthetics isoflurane and xenon. Anesthesiology 2000; 92:1055-66
44. Downie DL, Hall AC, Lieb WR, Franks NP: Effects of inhalational general anaesthetics on native glycine receptors in rat medullary neurones and recombinant glycine receptors in Xenopus oocytes. Br J Pharmacol 1996; 118:493-502
45. Bahr BA: Long-term hippocampal slices: A model system for investigating synaptic mechanisms and pathologic processes. J Neurosci Res 1995; 42:294-305
46. Crain SM: Development of specific synaptic network functions in organotypic central nervous system (CNS) cultures: Implications for transplantation of CNS neural cells in vivo. Methods 1998; 16:228-38
47. Finley M, Fairman D, Liu D, Li P, Wood A, Cho S: Functional validation of adult hippocampal organotypic cultures as an in vitro model of brain injury. Brain Res 2004; 1001:125-32
48. Frantseva M, Perez Velazquez JL, Tonkikh A, Adamchik Y, Carlen PL: Neurotrauma/neurodegeneration and mitochondrial dysfunction. Prog Brain Res 2002; 137:171-6
49. Frantseva MV, Kokarovtseva L, Perez Velazquez JL: Ischemiainduced brain damage depends on specific gap-junctional coupling. J Cereb Blood Flow Metab 2002; 22:453-62
50. Adembri C, Bechi A, Meli E, Gramigni E, Venturi L, Moroni F, De Gaudio AR, Pellegrini-Giampietro DE: Erythropoietin attenuates post-traumatic injury in organotypic hippocampal slices. J Neurotrauma 2004; 21:1103-12
51. Morrison B III, Saatman KE, Meaney DF, McIntosh TK: In vitro central nervous system models of mechanically induced trauma: A review. J Neurotrauma 1998; 15:911-28
52. Turtzo LC, Budde MD, Gold EM, Lewis BK, Janes L, Yarnell A, Grunberg NE, Watson W, Frank JA: The evolution of traumatic brain injury in a rat focal contusion model. NMR Biomed 2013; 26: 468-79
53. Servadei F, Nanni A, Nasi MT, Zappi D, Vergoni G, Giuliani G, Arista A: Evolving brain lesions in the first 12 hours after head injury: Analysis of 37 comatose patients. Neurosurgery 1995; 37:899-906; discussion 906-7
54. White CL, Griffith S, Caron JL: Early progression of traumatic cerebral contusions: Characterization and risk factors. J Trauma 2009; 67:508-14; discussion 514-5
55. Gray JJ, Bickler PE, Fahlman CS, Zhan X, Schuyler JA: Isoflurane neuroprotection in hypoxic hippocampal slice cultures involves increases in intracellular Ca2+ and mitogenactivated protein kinases. Anesthesiology 2005; 102:606-15
56. Montero M, Nielsen M, Rønn LC, Møller A, Noraberg J, Zimmer J: Neuroprotective effects of the AMPA antagonist PNQX in oxygen-glucose deprivation in mouse hippocampal slice cultures and global cerebral ischemia in gerbils. Brain Res 2007; 1177:124-35
57. Sullivan BL, Leu D, Taylor DM, Fahlman CS, Bickler PE: Isoflurane prevents delayed cell death in an organotypic slice culture model of cerebral ischemia. Anesthesiology 2002; 96:189-95
58. Berger AJ, Dieudonné S, Ascher P: Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J Neurophysiol 1998; 80:3336-40
59. Dopico JG, González-Hernández T, Pérez IM, García IG, Abril AM, Inchausti JO, Rodríguez Díaz M: Glycine release in the substantia nigra: Interaction with glutamate and GABA. Neuropharmacology 2006; 50:548-57
60. Heurteaux C, Guy N, Laigle C, Blondeau N, Duprat F, Mazzuca M, Lang-Lazdunski L, Widmann C, Zanzouri M, Romey G, Lazdunski M: TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO J 2004; 23:2684-95
61. Fahlenkamp AV, Rossaint R, Haase H, Al Kassam H, Ryang YM, Beyer C, Coburn M: The noble gas argon modifies extracellular signal-regulated kinase signaling in neurons and glial cells. Eur J Pharmacol 2012; 674:104-11
62. Head BP, Patel P: Anesthetics and brain protection. Curr Opin Anaesthesiol 2007; 20:395-9
63. Patel P: No magic bullets: The ephemeral nature of anesthetic-mediated neuroprotection. Anesthesiology 2004; 100:1049-51
64. Dyker AG, Lees KR: Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke. Stroke 1999; 30:986-92
65. Sanders RD, Franks NP, Maze M: Xenon: No stranger to anaesthesia. Br J Anaesth 2003; 91:709-17
66. Hemmings HC Jr, Mantz J: Xenon and the pharmacology of fear. Anesthesiology 2008; 109:954-5
67. Preckel B, Schlack W, Heibel T, Rütten H: Xenon produces minimal haemodynamic effects in rabbits with chronically compromised left ventricular function. Br J Anaesth 2002; 88:264-9